Inventiva S.A. (IVA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Inventiva S.A. (IVA) closed at USD 2.87 on 2026-10-14, a change of -45.5 % over the past year, with a market capitalization of USD 734.65M.

Inventiva S.A. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Inventiva S.A. key figures

Previous close

USD 2.87 (2026-10-14)

1-year change

-45.5 %

Market cap

USD 734.65M

Enterprise value

USD 707.49M

P/E ratio (trailing)

-4.64

P/E ratio (forward)

-4.17

EPS (trailing)

-0.67

EPS (forward)

-0.75

PEG ratio

n/a

Price to book

11.11

Revenue growth

-76.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.20

Employees

87

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Inventiva S.A.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Inventiva S.A. and compare it with other stocks.